Previous studies in patient-derived glioblastoma cells demonstrated that SAHA, VPA, MS275, LBH589, and Scriptaid are effective radiosensitizers of gliomas.64 However, the potential efficacy of SIRT1-specific pharmacologic inhibitors, such as EX-527 (Selisistat),65 for treatment of brain gliomas has not been investigated in preclinical studies or in clinical trials. Here, SIRT1 is linked to central nervous system cancer.